Savara (SVRA) Competitors $3.42 +0.11 (+3.32%) Closing price 04:00 PM EasternExtended Trading$3.42 0.00 (-0.15%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. IBRX, HRMY, RXRX, OCUL, IRON, CGON, BLTE, MESO, ADPT, and SRPTShould you be buying Savara stock or one of its competitors? The main competitors of Savara include ImmunityBio (IBRX), Harmony Biosciences (HRMY), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), Disc Medicine (IRON), CG Oncology (CGON), Belite Bio (BLTE), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Savara vs. Its Competitors ImmunityBio Harmony Biosciences Recursion Pharmaceuticals Ocular Therapeutix Disc Medicine CG Oncology Belite Bio Mesoblast Adaptive Biotechnologies Sarepta Therapeutics ImmunityBio (NASDAQ:IBRX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Do analysts prefer IBRX or SVRA? ImmunityBio currently has a consensus target price of $10.75, suggesting a potential upside of 353.59%. Savara has a consensus target price of $6.67, suggesting a potential upside of 94.93%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals & insiders believe in IBRX or SVRA? 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 76.8% of ImmunityBio shares are held by insiders. Comparatively, 5.1% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is IBRX or SVRA more profitable? Savara has a net margin of 0.00% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-648.57% N/A -113.86% Savara N/A -69.05%-54.84% Which has more volatility & risk, IBRX or SVRA? ImmunityBio has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Does the media refer more to IBRX or SVRA? In the previous week, Savara had 3 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Savara and 5 mentions for ImmunityBio. Savara's average media sentiment score of 1.34 beat ImmunityBio's score of 0.71 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Savara 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, IBRX or SVRA? Savara has lower revenue, but higher earnings than ImmunityBio. Savara is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M151.99-$413.56M-$0.48-4.94SavaraN/AN/A-$95.88M-$0.50-6.84 SummaryImmunityBio and Savara tied by winning 8 of the 16 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$591.11M$2.82B$5.75B$9.83BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-6.8422.6482.4426.63Price / SalesN/A720.78530.59110.56Price / CashN/A26.3325.7028.92Price / Book4.896.7910.646.56Net Income-$95.88M$32.94M$3.28B$266.04M7 Day Performance3.95%0.75%-0.08%-0.58%1 Month Performance32.05%8.36%10.35%6.24%1 Year Performance-18.76%0.53%48.99%22.22% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara3.1734 of 5 stars$3.42+3.3%$6.67+94.9%-22.5%$591.11MN/A-6.8420News CoverageAnalyst ForecastHigh Trading VolumeIBRXImmunityBio2.618 of 5 stars$2.25-2.6%$10.75+377.8%-39.7%$2.18B$14.74M-4.69590HRMYHarmony Biosciences4.2812 of 5 stars$37.42-1.2%$51.00+36.3%+3.1%$2.18B$714.73M12.07200Positive NewsRXRXRecursion Pharmaceuticals2.1045 of 5 stars$4.83-2.2%$7.00+44.9%-36.0%$2.14B$58.84M-2.71400Positive NewsOCULOcular Therapeutix3.6628 of 5 stars$11.87-3.5%$17.20+44.9%+44.0%$2.14B$63.72M-9.27230IRONDisc Medicine3.2633 of 5 stars$59.41-1.6%$98.30+65.5%+20.8%$2.10BN/A-13.2930News CoveragePositive NewsCGONCG Oncology3.0312 of 5 stars$25.42-5.6%$55.27+117.4%-25.5%$2.05B$1.14M-14.3661News CoverageAnalyst UpgradeBLTEBelite Bio2.6732 of 5 stars$63.62-1.2%$96.67+51.9%+34.3%$2.05BN/A-41.0510Positive NewsMESOMesoblast2.1969 of 5 stars$15.71-0.6%$18.00+14.6%+94.7%$2.02B$5.90M0.0080Gap DownADPTAdaptive Biotechnologies3.3001 of 5 stars$12.67-2.5%$12.38-2.3%+173.2%$1.98B$178.96M-15.45790Positive NewsSRPTSarepta Therapeutics4.7682 of 5 stars$18.06-10.7%$43.50+140.9%-86.6%$1.98B$1.90B-20.761,372Positive News Related Companies and Tools Related Companies IBRX Alternatives HRMY Alternatives RXRX Alternatives OCUL Alternatives IRON Alternatives CGON Alternatives BLTE Alternatives MESO Alternatives ADPT Alternatives SRPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
